NCT03970668View on ClinicalTrials.gov

Linagliptin in Post-renal Transplantation

CompletedOBSERVATIONAL
Enrollment

28

Participants

Timeline

Start Date

January 1, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

April 30, 2019

Conditions
Transplanted Kidney Complication
Interventions
DRUG

Linagliptin 5 mg Oral Tablet

Patients received linagliptin 5mg once daily orally plus a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)

DRUG

Insulin

Patients received a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)

All Listed Sponsors
collaborator

Hospital Regional de Alta Especialidad del Bajio

OTHER

lead

Universidad de Guanajuato

OTHER

NCT03970668 - Linagliptin in Post-renal Transplantation | Biotech Hunter | Biotech Hunter